Bath Savings Trust Co buys $9,182,853 stake in Celgene Corporation (CELG)

Celgene Corporation (CELG) : Bath Savings Trust Co scooped up 2,960 additional shares in Celgene Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 20, 2016. The investment management firm now holds a total of 85,406 shares of Celgene Corporation which is valued at $9,182,853.Celgene Corporation makes up approximately 2.81% of Bath Savings Trust Co’s portfolio.

Other Hedge Funds, Including , Quantres Asset Management Ltd added CELG to its portfolio by purchasing 27,200 company shares during the most recent quarter which is valued at $2,924,544. Celgene Corporation makes up approx 1.74% of Quantres Asset Management Ltd’s portfolio.Pennsylvania Trust Co boosted its stake in CELG in the latest quarter, The investment management firm added 751 additional shares and now holds a total of 39,620 shares of Celgene Corporation which is valued at $4,145,044. Celgene Corporation makes up approx 0.33% of Pennsylvania Trust Co’s portfolio.Marcus Capital boosted its stake in CELG in the latest quarter, The investment management firm added 50 additional shares and now holds a total of 16,450 shares of Celgene Corporation which is valued at $1,720,999. Celgene Corporation makes up approx 1.73% of Marcus Capital’s portfolio.Handelsbanken Fonder Ab boosted its stake in CELG in the latest quarter, The investment management firm added 14,000 additional shares and now holds a total of 369,310 shares of Celgene Corporation which is valued at $37,928,137. Celgene Corporation makes up approx 1.50% of Handelsbanken Fonder Ab’s portfolio.

Celgene Corporation opened for trading at $102.93 and hit $105.6 on the upside on Wednesday, eventually ending the session at $104.62, with a gain of 2.31% or 2.36 points. The heightened volatility saw the trading volume jump to 56,57,943 shares. Company has a market cap of $81,039 M.

On the company’s financial health, Celgene Corporation reported $1.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.27. The company had revenue of $2511.60 million for the quarter, compared to analysts expectations of $2577.08 million. The company’s revenue was up 20.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.07 EPS.

Many Wall Street Analysts have commented on Celgene Corporation. Stifel Initiated Celgene Corporation on Jul 15, 2016 to “Buy”, Price Target of the shares are set at $138.Company shares were Reiterated by Sun Trust Rbsn Humphrey on Apr 29, 2016 to “Buy”, Firm has raised the Price Target to $ 147 from a previous price target of $145 .

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Leave a Reply

Celgene Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Celgene Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.